Our Team
BRIM Biotechnology brings together experts across science, engineering, and technology disciplines to deliver a more efficient, less costly, drug development process. Our talented team has forged decades worth of strong global connections and experience. We operate based on a virtual team model, integrating our expert R&D operation team in Taiwan with our skilled overseas scientific team. We have years of experience working in technological and pharmaceutical development, regulatory affairs, and marketing and IP, with expertise across the field of innovative drug development, including pre-clinical toxicology, clinical pharmacology, and management. We harness the power of our team’s expertise in translational science to deliver a difference for patients.
Translational Science Expertise
BRIM R&D Operational Team
BRIM R&D
Operational Team
BRIM R&D
Operational Team
Pre-clinical & Toxicology
Dr. Frank Lee
Chief Scientific Officer
Dr. Frank Lee
Chief Scientific Officer
Vito Sasseville, D.V.M., Ph.D., Diplomate A.C.V.P.
Senior Consultant問
Vito Sasseville, D.V.M., Ph.D., Diplomate A.C.V.P.
Senior Consultant
Vito Sasseville supported the Drug Safety groups at Bristol-Myers Squibb, Millennium Pharmaceuticals (Takeda), and the Novartis Institutes of Biomedical. Vito is recognized for his work in the safety assessment of ocular and is currently the owner of Coastal Pharmaceutical Consulting.
Cheng-Wen Lin
Chief Technology Officer
Cheng-Wen Lin
Chief Technology Officer
Over 18 years of experience in ocular drug research and development, from discovery to marketing authorization, with expertise in pharmacology, formulation, and drug delivery technologies.
Clinical Pharmacology & Clinical Management
Wen Chyi Shyu, PhD
CEO
Wen Chyi Shyu, PhD
CEO
Vice President of Global Drug Metabolism and Pharmacokinetics at Takeda
30+ years of experience in drug metabolism and pharmacokinetics
Haishan Jang, PhD, MBA
Vice Chairman, CGS (Chief Global Strategist)
Haishan Jang, PhD, MBA
Vice Chairman, CGS (Chief Global Strategist)
Szu-Yun Leu, Ph.D.
Senior Consultant
Szu-Yun Leu, Ph.D.
Senior Consultant
Over 25 years’ experience in statistical consultation, grant preparation, study design and planning, database design and management, statistical analysis, and manuscript writing in various medical fields, including cancer research, exercise physiology, obesity, pulmonary disease, genomics, gas biomarkers, ophthalmology, and AIDS research.
CMC & Pharmaceutical Development
Dr. Wayne Liaw
Senior Consultant
Dr. Wayne Liaw
Senior Consultant
Previously held Senior Director positions at Otonomy and Optimer
Former director at Hollis-Eden pharma
Judy Yuan, Ph.D.
Senior Consultant
Judy Yuan, Ph.D.
Senior Consultant
Former Senior Director of Regulatory and CMC development at TaiGen Biotechnology, Taipei, Taiwan
Previously held Analytical R&D Senior Group Leader position at Abbot Laboratories (Now Abbie)
Mark Tucker, Ph.D.
Senior Consultant
Mark Tucker, Ph.D.
Senior Consultant
The President of Mark Tucker, LLC.
Expert in worldwide GMP Compliance with strong science background in biotechnology.
Regulatory Affairs
Dr. Li-Chun C. Wang”
Senior Consultant
Dr. Li-Chun C. Wang
Senior Consultant
President, LCWANG Regulatory Consulting, LLC
Previously held Vice President of Regulatory CMC at Solid Biosciences
40+ years of experience in drug development
Marketing and IP
Dr. Chyau Liang
Senior Consultant
Dr. Chyau Liang
Senior Consultant
Previously Partner at Osha Liang LLP
Former Professor at the University of Texas-Houston School of Medicine
SABs & KOLs
Dr. Pan-Chyr Yang
Scientific Board Member
Dr. Pan-Chyr Yang
Scientific Board Member
Academician at Academia Sinica and Professor at National Taiwan University
Previously President of National Taiwan University
Editor-in-Chief of MicroRNA and Lung Cancer: Targets and Therapy
Dr. Robert Ruffolo
Scientific Board Member
Dr. Robert Ruffolo
Scientific Board Member
Previously President of R&D and Corporate Senior Vice President of Wyeth Pharmaceuticals
Senior Vice President and Director of Research at SmithKline Beecham Pharmaceuticals
Chairman of the Cardiovascular Research Committee at Eli Lilly & Company
Dr. Eliot Lazar
Key Opinion Leader
Dr. Eliot Lazar
Key Opinion Leader
CEO at elCON Medical Consulting
Previously held Assistant Professor positions at the State University of NY and the University of Rochester
Victor L. Perez, Ph.D.
Scientific Board Member
Victor L. Perez, Ph.D.
Scientific Board Member
The Professor of Ophthalmology, University of Miami Miller School of Medicine.
Experienced and passionate Clinician-Scientist with a strong history of basic, translational and clinical research working with academic institutions in the field of cornea, ocular surface disease and uveitis.
Leadership Team
Wen Chyi Shyu, PhD
CEO
With more than three decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and management expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in drug metabolism to pharmacokinetics (DMPK) ranges from pre-clinical research discovery to clinical drug development and extended to life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.Wen Chyi brings to BRIM extensive industry experience and a passion for driving innovation in the drug discovery and development process. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee and Treasury of the New England Drug Metabolism Discussion Group (NEDMDG) to identify and improve the drug discovery process and to shorten the study turnaround time.Wen Chyi has a passion for developing people. Through training and motivation, research scientists can be developed into successful pharmaceutical executives to build international and multi-disciplinary teams. She, as an example, has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Wen Chyi Shyu, PhD
CEO
With more than three decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and management expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in drug metabolism to pharmacokinetics (DMPK) ranges from pre-clinical research discovery to clinical drug development and extended to life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.Wen Chyi brings to BRIM extensive industry experience and a passion for driving innovation in the drug discovery and development process. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee and Treasury of the New England Drug Metabolism Discussion Group (NEDMDG) to identify and improve the drug discovery process and to shorten the study turnaround time.Wen Chyi has a passion for developing people. Through training and motivation, research scientists can be developed into successful pharmaceutical executives to build international and multi-disciplinary teams. She, as an example, has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Mei-Hui Kuo, MS
Chief Operation Officer
Ms. Mei-Hui Kuo has over 35 years of experience in the biotechnology pharmaceutical industry. She was the founding COO of BRIM and now has returned to work with the new management team to reach BRIM′s operation goals. In her career, she has served successfully in many key positions including COO at Senhwa Biosciences, VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Mei-Hui Kuo, MS
Chief Operation Officer
Ms. Mei-Hui Kuo has over 35 years of experience in the biotechnology pharmaceutical industry. She was the founding COO of BRIM and now has returned to work with the new management team to reach BRIM′s operation goals. In her career, she has served successfully in many key positions including COO at Senhwa Biosciences, VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Frank W. Lee, PhD
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs. Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Frank W. Lee, PhD
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs. Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr. Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. Maria received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr. Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. Maria received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Cheng-Wen Lin PhD
Chief Technology Officer
Over 18 years of experience in ocular drug research and development, from discovery to marketing authorization, with expertise in pharmacology, formulation, and drug delivery technologies.
Cheng-Wen Lin PhD
Chief Technology Officer
Over 18 years of experience in ocular drug research and development, from discovery to marketing authorization, with expertise in pharmacology, formulation, and drug delivery technologies.
Scientific Consultants
Chyau Liang, PhD, JD
Senior IP Law Consultant
Chyau Liang, PhD, JD
Senior IP Law Consultant
Wayne Liaw, PhD
Senior Formulation & CMC Consultant
Wayne Liaw, PhD
Senior Formulation & CMC Consultant
Dr. Li-Chun C. Wang
Senior Consultant
President, LCWANG Regulatory Consulting, LLC
Previously held Vice President of Regulatory CMC at Solid Biosciences
40+ years of experience in drug development
Dr. Li-Chun C. Wang
Senior Consultant
President, LCWANG Regulatory Consulting, LLC
Previously held Vice President of Regulatory CMC at Solid Biosciences
40+ years of experience in drug development
Vito Sasseville, D.V.M., Ph.D., Diplomate A.C.V.P.
Senior Consultant
Vito Sasseville supported the Drug Safety groups at Bristol-Myers Squibb, Millennium Pharmaceuticals (Takeda), and the Novartis Institutes of Biomedical. Vito is recognized for his work in the safety assessment of ocular and is currently the owner of Coastal Pharmaceutical Consulting.
Vito Sasseville, D.V.M., Ph.D., Diplomate A.C.V.P.
Senior Consultant
Vito Sasseville supported the Drug Safety groups at Bristol-Myers Squibb, Millennium Pharmaceuticals (Takeda), and the Novartis Institutes of Biomedical. Vito is recognized for his work in the safety assessment of ocular and is currently the owner of Coastal Pharmaceutical Consulting.
Judy Yuan, Ph.D.
Senior Consultant
- Former Senior Director of Regulatory and CMC development at TaiGen Biotechnology, Taipei, Taiwan
- Previously held Analytical R&D Senior Group Leader position at Abbot Laboratories (Now Abbie)
Judy Yuan, Ph.D.
Senior Consultant- Former Senior Director of Regulatory and CMC development at TaiGen Biotechnology, Taipei, Taiwan
- Previously held Analytical R&D Senior Group Leader position at Abbot Laboratories (Now Abbie)
Mark Tucker, Ph.D.
Senior Consultant
- The President of Mark Tucker, LLC.
- Expert in worldwide GMP Compliance with strong science background in biotechnology.
Mark Tucker, Ph.D.
Senior Consultant- The President of Mark Tucker, LLC.
- Expert in worldwide GMP Compliance with strong science background in biotechnology.
Szu-Yun Leu, Ph.D.
Senior Consultant
Over 25 years’ experience in statistical consultation, grant preparation, study design and planning, database design and management, statistical analysis, and manuscript writing in various medical fields, including cancer research, exercise physiology, obesity, pulmonary disease, genomics, gas biomarkers, ophthalmology, and AIDS research.
Szu-Yun Leu, Ph.D.
Senior Consultant
Over 25 years’ experience in statistical consultation, grant preparation, study design and planning, database design and management, statistical analysis, and manuscript writing in various medical fields, including cancer research, exercise physiology, obesity, pulmonary disease, genomics, gas biomarkers, ophthalmology, and AIDS research.